Evidence
Aliment Pharmacol Ther. 2024 May;59(10):1294-1295. doi: 10.1111/apt.17992.
NO ABSTRACT
PMID:38652769 | DOI:10.1111/apt.17992
Add to Google Keep
Estimated reading time: 1 minute(s)
Latest: Psychiatryai.com #RAISR4D
Real-Time Evidence Search [Psychiatry]
Editorial: Crystalising the burden of steatotic liver disease-Authors’ reply
🌐 90 Days
VR Related Evidence Matrix
- Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population
- Review article: Current indications and selection criteria for early liver transplantation in severe alcohol-associated hepatitis
- Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction-associated steatotic liver disease - The Gut and Obesity in Asia (GO-ASIA) Study
- Meta-analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non-alcoholic steatohepatitis and non-alcoholic steatohepatitis-related fibrosis
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- The double roles of T cell-mediated immune response in the progression of MASLD
- Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China
- Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?
- The promise of N-acetylcysteine in the treatment of obsessive-compulsive disorder
- Pharmacogenetic testing of CYP2D6, CYP2C19 and CYP2C9 in Denmark: Agreement between publicly funded genotyping tests and the subsequent phenotype classification
- Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis
- Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults
- Plastic compounds and liver diseases: Whether bisphenol A is the only culprit
- Correction to "Hepatobiliary and Pancreatic: Challenges in the diagnosis of hepatic nodules in patients with alcoholic liver cirrhosis"
- Changes in the etiology of liver cirrhosis and the corresponding management strategies
- COVID-19 in Individuals with Chronic Liver Diseases
- Obituary: Travis Thompson-Editorial
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Home monitoring to detect progression of interstitial lung disease: A prospective cohort study
- A child with Kawasaki disease and acute pancreatitis: Atypical presentation
- Editorial on common mental health disorders and cognitive decline in a longitudinal Down syndrome cohort
- Slow disease progression and characteristic TDP-43 inclusions in a patient with familial amyotrophic lateral sclerosis carrying a TARDBP G357S variant
- Occult liver disease: a multinational perspective
- Mannose Supplementation Curbs Liver Steatosis and Fibrosis in Murine MASH by Inhibiting Fructose Metabolism
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- Traumatic Brain Injury Effects on the Next Generation
- Brain Connectivity: A Journal of Clinical Neurology, Neuroscience, & Neuroimaging
- An aggressive mediastinal EBV-associated large B cell lymphoma
- Author's reply: The importance of professional training to foster the implementation of Artificial Intelligence in the clinical setting of liver diseases
- The Global Epidemic of Metabolic Fatty Liver Disease
- From the Editor-in-Chief's Desk: Advances in Patient-Centered Treatment for Attention-Deficit/Hyperactivity Disorder
- Hedan tablet ameliorated non-alcoholic steatohepatitis by moderating NF-kappaB and lipid metabolism-related pathways via regulating hepatic metabolites
- Editorial perspective: Transforming child and adolescent mental health services and systems (CAMHSS) around the globe - the importance of diversity, inclusion and equity in CAMHSS research
- A comment and correction
- When I say … active learning
- When I say … inclusive teaching
- The systematic review and meta-analysis of cytisine
- An update of contemporary insulin therapy
- Response letter: Complexities in pericyte markers
- GUIDE dementia model: Opportunities for serious illness care
- Collaborative research for psychosis prediction and prevention
- Neuroaxonal damage as a mechanism underlying late-life depression
- PCN Art Brut Series No. 37, Artwork Description
- Mild cognitive impairment decreases the accuracy of own memory monitoring
- Addiction Lives
- Role of Angiotensin II in Non-Alcoholic Steatosis Development
- Meeting report of the 20th International Congress of Neuropathology (ICN) 2023 in Berlin
- Law not loopholes: Medical aid in dying for those with dementia
- Berberine prevents NAFLD and HCC by modulating metabolic disorders
- "My kid has autism": An interesting conversation with ChatGPT
- Obsessive-compulsive disorder: Taking the long view
- Patient and public involvement and engagement (PPIE) in research: The Golden Thread
- Does recency of prodromal symptom onset or worsening matter for psychosis prediction?
- The PSYCHS instrument to assess criteria for clinical high risk of psychosis
- The lifestyle of psoriasis patients and their motivation to change
- Risk factors of delirium after gastrointestinal surgery: A meta-analysis
- Training and supporting subspecialty clinician-scientists in aging research through GEMSSTAR and Clin-STAR
- Commentary on Aminesmaeili et al.: Non-abstinence outcomes in stimulant clinical trials-Why deny improvement?
- Commentary on Carrasquilla et al.: Smoking and obesity; uncovering causal mechanisms through triangulation of different methods
- Can generative artificial intelligence facilitate illustration of- and communication regarding hallucinations and delusions?
Evidence Blueprint
Editorial: Crystalising the burden of steatotic liver disease-Authors’ reply
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
Save Evidence Blueprint
Save as PDF
Editorial: Crystalising the burden of steatotic liver disease-Authors’ reply
🌐 365 Days
VR Related Evidence Matrix
- Editorial: optimal combination of non-invasive tests to determine significant fibrosis in non-alcoholic fatty liver disease-authors' reply
- Editorial: mitochondrial respiratory chain activity-a potential link with disease severity and treatment response in alcoholic hepatitis. Authors' reply
- Editorial: optimal combination of non-invasive tests to determine significant fibrosis in non-alcoholic fatty liver disease
- Editorial: mitochondrial respiratory chain activity-a potential link with disease severity and treatment response in alcoholic hepatitis
- Editorial: buspirone for gastroparesis-an intriguing option for a challenging condition
- Letter: higher severe outcomes among Helicobacter pylori-related lean patients with non-alcoholic fatty liver disease and metabolic comorbidities
- Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
- Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population
- The silent burden of non-alcoholic fatty liver disease in the elderly: A global burden of disease analysis
- Review article: Current indications and selection criteria for early liver transplantation in severe alcohol-associated hepatitis
- Systematic review and meta-analysis: Association between liver fibrosis and subclinical atherosclerosis in nonalcoholic fatty liver disease
- Meta-analysis: Impact of intragastric balloon therapy on NAFLD-related parameters in patients with obesity
- Epidemiology and risk factors for histopathologic characteristics of non-alcoholic fatty liver disease in South America
- Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI-PDFF in NAFLD
- The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma
- Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction-associated steatotic liver disease - The Gut and Obesity in Asia (GO-ASIA) Study
- Meta-analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non-alcoholic steatohepatitis and non-alcoholic steatohepatitis-related fibrosis
- MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease
- Systematic review: Glycomics as diagnostic markers for hepatocellular carcinoma
- Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis
- Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: A randomised trial
- First in human randomised trial of J2H-1702: A novel 11β-hydroxysteroid dehydrogenase type 1 inhibitor for non-alcoholic steatohepatitis treatment
- Associations of the Harvard Automated Phone Task and Alzheimer's Disease Pathology in Cognitively Normal Older Adults: Preliminary Findings
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- Steatotic hepatocyte-derived extracellular vesicles promote β-cell apoptosis and diabetes via microRNA-126a-3p
- Potential Mechanisms Involving in the Pathogenesis of MASLD and Targets for Pharmacotherapy. Advancements in Metabolic Associated Steatotic Liver Disease (MASLD) Research: Diagnostics, Small Molecule Developments and Future Directions
- Letter regarding 'Association of thyroid function with non-alcoholic fatty liver disease in recent-onset diabetes'
- Commentary: The evidence base regarding the long-term effects of childhood mental disorder treatments needs to be strengthened - reply to Dekkers et al. (2023)
- The double roles of T cell-mediated immune response in the progression of MASLD
- Relationship of ferritin and hepcidin with disease severity in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus
- Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China
- Reply to: Comment on: Association of sulfonylureas with the risk of dementia: A population-based cohort study
- Reply to: Disease latency and new-user versus prevalent-user cohort designs: Implications for pharmacoepidemiology in dementia
- MBOAT7 in liver and extrahepatic diseases
- Liver disease mortality and hospitalisations among people with type 2 diabetes mellitus: A population-based study
- Steatotic liver disease is the most important somatic determinant of quality of life in patients with obesity: A cross-sectional study
- Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?
- Therapeutic management of metabolic dysfunction associated steatotic liver disease
- The promise of N-acetylcysteine in the treatment of obsessive-compulsive disorder
- Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
- Pharmacogenetic testing of CYP2D6, CYP2C19 and CYP2C9 in Denmark: Agreement between publicly funded genotyping tests and the subsequent phenotype classification
- The significance of omega-3 fatty acids in the treatment of non-alcoholic fatty liver disease
- From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
- Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
- Exclusive liquor and cocktail consumption is associated with at-risk fibrosis among nonheavy alcohol users with metabolic dysfunction-associated steatotic liver disease
- Reply to Ng: a closer look at late-onset psychoses for the general internist
- Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype
- Reply to: Positive aspects of caregiving attenuate the relationship between behavioral bother and anxiety and depressive symptoms in dementia family caregivers. Geriatr. Gerontol. Int. 2023;1. https://doi.org/10.1111/ggi.1460
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Editorial: Prevention is the best cure - or is it? A cautionary tale
- Current and future treatment for alcoholic-related liver diseases
- Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings
- Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis
- The Landscape of Aberrant Alternative Splicing Events in Steatotic Liver Graft Post Transplantation via Transcriptome-Wide Analysis
- Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults
- Non-alcoholic fatty liver disease, women's health and the role of the environment
- Plastic compounds and liver diseases: Whether bisphenol A is the only culprit
- Correction to "Hepatobiliary and Pancreatic: Challenges in the diagnosis of hepatic nodules in patients with alcoholic liver cirrhosis"
- Changes in the etiology of liver cirrhosis and the corresponding management strategies
- Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Metabolism-related signalling pathways involved in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease